Strategic Nanotech Target biopharma and contract development organizations (CDMOs) with Aphios’ double-encapsulated mRNA vaccine and room-temperature stable formulations to address distribution challenges, cold-chain limitations, and single-dose regimens in global immunization programs.

CNS and Oncology Position Bryoids and polymer nanosphere delivery platforms as potential therapeutics for CNS disorders and cancer indications, aligning with partnerships or grant-funded programs focused on Alzheimer’s, MS, glaucoma, and related CNS diseases.

Opioid Disorder Leverage NIH SBIR experience and ongoing CBD-in-nanosphere delivery programs to pursue new funding and partnerships for chronic opioid use disorder relapse therapies, especially with extended-release, combination formulations.

Botanical Drug Focus Explore collaborations to advance Zindol, a ginger-derived botanical candidate for chemotherapy-induced nausea and vomiting, targeting oncology support teams and hospital formularies seeking non-synthetic adjunct therapies.

Global GMP Readiness Highlight scalable, virus-free biologics platforms and room-temperature stable manufacturing capabilities to attract CDMOs and partners seeking robust, sustainable supply chains and reduced cold-chain costs across biotherapeutics and vaccines.